Q-omics provides the consensus-scored GFRAL profile across patient tissues and cancer cell-line models. GFRAL expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GFRAL is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, GFRAL RNA expression shows 6,748 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, BRCA, and TGCT as cancer lineages where GFRAL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GFRAL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GFRAL survival associations across molecular data types. GFRAL RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GFRAL RNA expression–survival associations across cancer types. High GFRAL expression shows unfavorable associations in BLCA, READ, KIRC, OV and ACC, but favorable associations in PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GFRAL RNA expression.
This table summarizes GFRAL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GFRAL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GFRAL shows lower tumor expression in BRCA and COAD. The BRCA box plot shows higher GFRAL RNA expression in normal versus tumor tissue (log2 FC = −0.144, t-test p < 0.001).
This table shows molecular features associated with GFRAL in patient tissues and cancer cell lines. In patient samples, GFRAL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GFRAL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
